Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 35

Sort by

Sort Order Select

Journal Articles

Risk Factors and Outcomes for Hematotoxicity Following Tisagenlecleucel for Pediatric B-Acute Lymphoblastic Leukemia

Blood (2023) 142 (Supplement 1): 2133.

https://doi.org/10.1182/blood-2023-189921

Published: 2023

Journal Articles

Efficacy of Treatment Options for Children with Steroid-Refractory Acute Gvhd

Prakash Satwani, Sonali Chaudhury, Mihaela Georgiana Musat, Jodie Wehling, Gwen Shang

Blood (2023) 142 (Supplement 1): 7013.

https://doi.org/10.1182/blood-2023-187609

Published: 2023

Journal Articles

Establishing Costs for Commercial Chimeric Antigen Receptor T-Cell (Tisagenlecleucel; Kymriah) in Children and Young Adult B-Cell Acute Lymphoblastic Leukemia; A Merged Analysis from the Prwcc and PHIS

Blood (2023) 142 (Supplement 1): 6912.

https://doi.org/10.1182/blood-2023-187462

Published: 2023

Journal Articles

Obesity Associates with Inferior Outcomes and Toxicity in Pediatric and Young Adult Patient with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Treated with Commercially Manufactured Tisagenlecleucel

Blood (2022) 140 (Supplement 1): 10419–10421.

https://doi.org/10.1182/blood-2022-163336

Published: 2022

Journal Articles

Antigen Directed Therapy Pre-Transplant Confers Superior Post-Transplant Survival Outcome Compared to Conventional Chemotherapy in Pediatric Patients with Relapsed and Refractory B-ALL

Blood (2022) 140 (Supplement 1): 7763–7765.

https://doi.org/10.1182/blood-2022-160272

Published: 2022

Journal Articles

Standard Cytogenetic Risk Stratification Is Not Predictive of CD19 CAR Outcomes and Impact of Disease Burden Varies between Cytogenetic Risk Groups

Blood (2022) 140 (Supplement 1): 10386–10388.

https://doi.org/10.1182/blood-2022-165951

Published: 2022

Journal Articles

Peripheral Blast Count at Apheresis Acts Independent of Disease Burden As a Risk Factor for Survival Following Tisagenlecleucel in Children and Young Adults

Blood (2022) 140 (Supplement 1): 4661–4663.

https://doi.org/10.1182/blood-2022-169603

Published: 2022

Journal Articles

Out-of-specification tisagenlecleucel does not compromise safety or efficacy in pediatric acute lymphoblastic leukemia

Blood (2021) 138 (21): 2138–2142.

https://doi.org/10.1182/blood.2021012392

Published: 2021

Journal Articles

Late Effects after Allogeneic Hematopoietic Cell Transplantation Among Children and Adolescents with Non-Malignant Disorders: A Report from the Center for International Blood and Marrow Transplant Research (CIBMTR)

Justine M. Kahn, Stephanie Bo-Subait, David K. Buchbinder, Betty K. Hamilton, Helene Schoemans, Ruta Brazauskas, Rachel Phelan, Prakash Satwani

Blood (2021) 138 (Supplement 1): 412.

https://doi.org/10.1182/blood-2021-151446

Published: 2021

Journal Articles

Disease Burden Impacts Outcomes in Pediatric and Young Adult B-Cell Acute Lymphoblastic Leukemia after Commercial Tisagenlecleucel: Results from the Pediatric Real World CAR Consortium (PRWCC)

Blood (2020) 136 (Supplement 1): 14–15.

https://doi.org/10.1182/blood-2020-134472

Published: 2020

Journal Articles

Real-World Treatment of Pediatric Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Using Tisagenlecleucel That Is out of Specification for Commercial Release

Blood (2020) 136 (Supplement 1): 42–44.

https://doi.org/10.1182/blood-2020-136674

Published: 2020

Journal Articles

Health Care Utilization and Cost of Allogeneic Hematopoietic Cell Transplantation in Children with Malignant and Non-Malignant Diseases

Angela Ricci, MD, Zhezhen Jin, PhD, Wallace Bourgeois, MD, Matt Hall, PhD, Prakash Satwani, MD

Blood (2017) 130 (Supplement 1): 2109.

https://doi.org/10.1182/blood.V130.Suppl_1.2109.2109

Published: 2017

Journal Articles

Role of Donor Source on Clinical Outcomes and Inpatient Resource Utilization for Hematopoietic Cell Transplantation in Children with Acute Leukemia

Staci D Arnold, MD MBA, Ruta Brazauskas, PhD, Naya He, MPH, Yimei Li, PhD, Prakash Satwani, MD MBBS, Michael A Pulsipher, MD, Matt Hall, PhD, Yoshiko Atsuta, MD PhD, Jignesh D Dalal, MD, Theresa Hahn, PhD, Carmem Bonfim, MD, Nandita Khera, MD, Richard Aplenc, MD PhD, Wael Saber, MD MS

Blood (2016) 128 (22): 3575.

https://doi.org/10.1182/blood.V128.22.3575.3575

Published: 2016

Journal Articles

A Study of Predictors of Clinical Outcomes and Healthcare Utilization in Children with Sickle Cell Disease Undergoing Allogeneic Hematopoietic Cell Transplantation

Prakash Satwani, MD MBBS, Ruta Brazauskas, PhD, Staci D. Arnold, MD MBA, Naya He, PhD, Yimei Li, PhD, Richard Aplenc, MD PhD, Matt Hall, PhD, Yoshiko Atsuta, MDPhD, Jignesh D Dalal, MD, Theresa Hahn, PhD, ZheZhen Jin, PhD, Carmem Sales-Bonfim, MD PhD, Nandita Khera, MD, Wael Saber, MD MS

Blood (2015) 126 (23): 528.

https://doi.org/10.1182/blood.V126.23.528.528

Published: 2015

Journal Articles

Allogeneic hematopoietic cell transplantation for XIAP deficiency: an international survey reveals poor outcomes

Blood (2013) 121 (6): 877–883.

https://doi.org/10.1182/blood-2012-06-432500

Published: 2013

Journal Articles

Differential Genomic and Proteomic Signatures In Cord Blood (CB) Vs Peripheral Blood (PB) CD56 +Dim NK Cells: Over Expression of CD34 In CB Vs PB CD56 +Dim NK Cells

Nancy S Day, PhD, Evan Shereck, MD, Janet Ayello, MS, MT(ASCP), Catherine McGuinn, MD, Prakash Satwani, MD, Juliana Atallah, Carmella van de Ven, MA, Ronald J Wapner, MD, Megan S. Lim, MD, PhD, Mitchell S. Cairo, MD

Blood (2010) 116 (21): 2781.

https://doi.org/10.1182/blood.V116.21.2781.2781

Published: 2010

Journal Articles

Dose Escalation of Clofarabine In Combination with Cytarabine and Total Body Irradiation (TBI) Followed by Allogeneic Stem Cell Transplantation (AlloSCT) In Children, Adolescents and Young Adults (CAYA) with Poor-Risk Acute Leukemia

Mark B Geyer, AB, Angela M Ricci, BA, Lauren Harrison, RN, MSN, Deirdre Duffy, BS, Monica Bhatia, MD, James H Garvin, Jr., MD, Diane George, MD, Prakash Satwani, MD, Alexandra C Cheerva, MD, MS, Julie Talano, MD, Fevzi Ozkaynak, MD, Theodore B. Moore, MD, MS, Joseph Schwartz, MD, Lee Ann Baxter-Lowe, PhD, Mitchell S. Cairo, MD

Blood (2010) 116 (21): 36.

https://doi.org/10.1182/blood.V116.21.36.36

Published: 2010

Journal Articles

Romedepsin (RM), a Histone Deacytelase Inhibitor (HDACi), Significantly Increases the Expression of NKG2D Ligands, MIC A/B, In Pediatric Leukemia/Lymphoma Cells (LL), Resulting In Enhanced In Vitro and In Vivo NK Cytotoxicity In NOD-SCID Mice: Translational Approach for Adoptive NK Cell Targeted Immunotherapy

Prakash Satwani, MD, Aniket Saha, MD, Sejal Bavishi, BS, Frances Zhao, MS, Janet Ayello, MS, MT(ASCP), Carmella van de Ven, MA, Mitchell S. Cairo, MD

Blood (2010) 116 (21): 4297.

https://doi.org/10.1182/blood.V116.21.4297.4297

Published: 2010

Journal Articles

A Pilot Study of Reduced Toxicity Conditioning (RTC) with Busulfan (Bu), Fludarabine (Flu), and Alemtuzumab Followed by Allogeneic Stem Cell Transplantation (AlloSCT) to Induce Sustained Mixed Donor Chimerism In Patients with Symptomatic Sickle Cell Disease (SCD)

Monica Bhatia, MD, Mark B Geyer, AB, Courtney Baker, RN, MSN, PNP, Erin Morris, RN, BSN, Deirdre Duffy, BS, Diane George, MD, James H Garvin, Jr., MD, PhD, Prakash Satwani, MD, Joseph Schwartz, MD, Sandra Foley, CPNP, Ria Hawks, CPNP, Elana Hamburger-Smilow, CPNP, Lee Ann Baxter-Lowe, PhD, Mitchell S. Cairo, MD

Blood (2010) 116 (21): 3504.

https://doi.org/10.1182/blood.V116.21.3504.3504

Published: 2010

Journal Articles

Reduced Toxicity Conditioning (RTC) Compared to Myeloablative Conditioning (MAC) Prior to Unrelated Cord Blood Transplantation (UCBT) in Pediatric Recipients Was Associated with Similar but Also Delayed Time to Immune Reconstitution and a Concomitant Significant Decrease in Grade II-IV Agvhd.

Jason Freedman, M.D., Diane George, MD, Judith Jacobson, DrPH, MBA, Mark Geyer, AB, Carmella van de Ven, MA, Nathifa Fearon, RN, MSN, Claire Fanelli, RN, BSN, Bradford Tallamy, BA, Prakash Satwani, MD, Monica Bhatia, MD, James H. Garvin, Jr., MD, M. Brigid Bradley, MD, Tracey Schonfeld, RN, BSN, Lauren Harrison, RN, Erin Morris, RN, Joseph Schwartz, MD, Lee Ann Baxter-Lowe, PhD, Mitchell S. Cairo, MD

Blood (2009) 114 (22): 2304.

https://doi.org/10.1182/blood.V114.22.2304.2304

Published: 2009

NARROW

Risk Factors and Outcomes for Hematotoxicity Following Tisagenlecleucel for Pediatric B-Acute Lymphoblastic Leukemia

Efficacy of Treatment Options for Children with Steroid-Refractory Acute Gvhd

Establishing Costs for Commercial Chimeric Antigen Receptor T-Cell (Tisagenlecleucel; Kymriah) in Children and Young Adult B-Cell Acute Lymphoblastic Leukemia; A Merged Analysis from the Prwcc and PHIS

Obesity Associates with Inferior Outcomes and Toxicity in Pediatric and Young Adult Patient with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Treated with Commercially Manufactured Tisagenlecleucel

Antigen Directed Therapy Pre-Transplant Confers Superior Post-Transplant Survival Outcome Compared to Conventional Chemotherapy in Pediatric Patients with Relapsed and Refractory B-ALL

Standard Cytogenetic Risk Stratification Is Not Predictive of CD19 CAR Outcomes and Impact of Disease Burden Varies between Cytogenetic Risk Groups

Peripheral Blast Count at Apheresis Acts Independent of Disease Burden As a Risk Factor for Survival Following Tisagenlecleucel in Children and Young Adults

Out-of-specification tisagenlecleucel does not compromise safety or efficacy in pediatric acute lymphoblastic leukemia

Late Effects after Allogeneic Hematopoietic Cell Transplantation Among Children and Adolescents with Non-Malignant Disorders: A Report from the Center for International Blood and Marrow Transplant Research (CIBMTR)

Disease Burden Impacts Outcomes in Pediatric and Young Adult B-Cell Acute Lymphoblastic Leukemia after Commercial Tisagenlecleucel: Results from the Pediatric Real World CAR Consortium (PRWCC)

Real-World Treatment of Pediatric Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Using Tisagenlecleucel That Is out of Specification for Commercial Release

Health Care Utilization and Cost of Allogeneic Hematopoietic Cell Transplantation in Children with Malignant and Non-Malignant Diseases

Role of Donor Source on Clinical Outcomes and Inpatient Resource Utilization for Hematopoietic Cell Transplantation in Children with Acute Leukemia

A Study of Predictors of Clinical Outcomes and Healthcare Utilization in Children with Sickle Cell Disease Undergoing Allogeneic Hematopoietic Cell Transplantation

Allogeneic hematopoietic cell transplantation for XIAP deficiency: an international survey reveals poor outcomes

Differential Genomic and Proteomic Signatures In Cord Blood (CB) Vs Peripheral Blood (PB) CD56 +Dim NK Cells: Over Expression of CD34 In CB Vs PB CD56 +Dim NK Cells

Dose Escalation of Clofarabine In Combination with Cytarabine and Total Body Irradiation (TBI) Followed by Allogeneic Stem Cell Transplantation (AlloSCT) In Children, Adolescents and Young Adults (CAYA) with Poor-Risk Acute Leukemia

A Pilot Study of Reduced Toxicity Conditioning (RTC) with Busulfan (Bu), Fludarabine (Flu), and Alemtuzumab Followed by Allogeneic Stem Cell Transplantation (AlloSCT) to Induce Sustained Mixed Donor Chimerism In Patients with Symptomatic Sickle Cell Disease (SCD)

Reduced Toxicity Conditioning (RTC) Compared to Myeloablative Conditioning (MAC) Prior to Unrelated Cord Blood Transplantation (UCBT) in Pediatric Recipients Was Associated with Similar but Also Delayed Time to Immune Reconstitution and a Concomitant Significant Decrease in Grade II-IV Agvhd.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only